FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974947034> ?p ?o ?g. }

• W1974947034 endingPage "769" @default.
• W1974947034 startingPage "763" @default.
• W1974947034 abstract "We performed a clinical open trial to evaluate the efficacy and the adverse side effects of a single therapy with FK506 in refractory uveitis as a multicenter study in Japan. Fifty-three patients (41 patients with Behçet's disease, five with Vogt-Koyanagi-Harada disease, four with idiopathic retinal vasculitis, and three with other forms of uveitis) were enrolled in the study. FK506 was given orally for 12 weeks. Treatment with FK506 exhibited therapeutic effects in a dosage-dependent manner: the effectiveness was 38% in patients treated with an initial dosage of 0.05 mg/kg of body weight per day, 60% with 0.10 mg/kg of body weight per day, 83% with 0.15 mg/kg of body weight per day, and 79% with 0.20 mg/kg of body weight per day. Overall efficacy with dosage adjustment when needed was 76.5% at the conclusion of the study at the end of the 12th week. The FK506 therapy induced a variety of adverse side effects, the incidence of which depended on the dosage. The major side effects were renal impairment (28.3%, 15 of 53 patients), neurologic symptoms (20.8%, 11 of 53 patients), gastrointestinal symptoms (18.9%, ten of 53 patients), and hyperglycemia (13.2%, seven of 53 patients). The trough level of FK506 in the whole blood correlated with both the efficacy of the therapy and with the incidence of adverse effects. It is recommended to maintain the trough level between 15 and 25 ng/ml. On the basis of these results, a daily dosage of 0.10 to 0.15 mg/kg of body weight per day was suggested as an appropriate therapeutic dosage for refractory uveitis. We performed a clinical open trial to evaluate the efficacy and the adverse side effects of a single therapy with FK506 in refractory uveitis as a multicenter study in Japan. Fifty-three patients (41 patients with Behçet's disease, five with Vogt-Koyanagi-Harada disease, four with idiopathic retinal vasculitis, and three with other forms of uveitis) were enrolled in the study. FK506 was given orally for 12 weeks. Treatment with FK506 exhibited therapeutic effects in a dosage-dependent manner: the effectiveness was 38% in patients treated with an initial dosage of 0.05 mg/kg of body weight per day, 60% with 0.10 mg/kg of body weight per day, 83% with 0.15 mg/kg of body weight per day, and 79% with 0.20 mg/kg of body weight per day. Overall efficacy with dosage adjustment when needed was 76.5% at the conclusion of the study at the end of the 12th week. The FK506 therapy induced a variety of adverse side effects, the incidence of which depended on the dosage. The major side effects were renal impairment (28.3%, 15 of 53 patients), neurologic symptoms (20.8%, 11 of 53 patients), gastrointestinal symptoms (18.9%, ten of 53 patients), and hyperglycemia (13.2%, seven of 53 patients). The trough level of FK506 in the whole blood correlated with both the efficacy of the therapy and with the incidence of adverse effects. It is recommended to maintain the trough level between 15 and 25 ng/ml. On the basis of these results, a daily dosage of 0.10 to 0.15 mg/kg of body weight per day was suggested as an appropriate therapeutic dosage for refractory uveitis." @default.
• W1974947034 created "2016-06-24" @default.
• W1974947034 creator A5004547585 @default.
• W1974947034 creator A5012974114 @default.
• W1974947034 creator A5016686689 @default.
• W1974947034 creator A5018494644 @default.
• W1974947034 creator A5024370562 @default.
• W1974947034 creator A5029122307 @default.
• W1974947034 creator A5030939291 @default.
• W1974947034 creator A5031935488 @default.
• W1974947034 creator A5034645642 @default.
• W1974947034 creator A5048857512 @default.
• W1974947034 creator A5053735930 @default.
• W1974947034 creator A5083214362 @default.
• W1974947034 creator A5084784449 @default.
• W1974947034 date "1993-06-01" @default.
• W1974947034 modified "2023-10-18" @default.
• W1974947034 title "A Clinical Trial of FK506 in Refractory Uveitis" @default.
• W1974947034 cites W1562075782 @default.
• W1974947034 cites W2054396659 @default.
• W1974947034 cites W2063962500 @default.
• W1974947034 cites W2089850443 @default.
• W1974947034 cites W2093662571 @default.
• W1974947034 cites W2127691109 @default.
• W1974947034 cites W2167839140 @default.
• W1974947034 cites W2272000518 @default.
• W1974947034 cites W2329573625 @default.
• W1974947034 cites W2782175582 @default.
• W1974947034 doi "https://doi.org/10.1016/s0002-9394(14)73645-1" @default.
• W1974947034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7685147" @default.
• W1974947034 hasPublicationYear "1993" @default.
• W1974947034 type Work @default.
• W1974947034 sameAs 1974947034 @default.
• W1974947034 citedByCount "112" @default.
• W1974947034 countsByYear W19749470342012 @default.
• W1974947034 countsByYear W19749470342013 @default.
• W1974947034 countsByYear W19749470342014 @default.
• W1974947034 countsByYear W19749470342015 @default.
• W1974947034 countsByYear W19749470342016 @default.
• W1974947034 countsByYear W19749470342017 @default.
• W1974947034 countsByYear W19749470342018 @default.
• W1974947034 countsByYear W19749470342019 @default.
• W1974947034 countsByYear W19749470342020 @default.
• W1974947034 countsByYear W19749470342021 @default.
• W1974947034 countsByYear W19749470342022 @default.
• W1974947034 countsByYear W19749470342023 @default.
• W1974947034 crossrefType "journal-article" @default.
• W1974947034 hasAuthorship W1974947034A5004547585 @default.
• W1974947034 hasAuthorship W1974947034A5012974114 @default.
• W1974947034 hasAuthorship W1974947034A5016686689 @default.
• W1974947034 hasAuthorship W1974947034A5018494644 @default.
• W1974947034 hasAuthorship W1974947034A5024370562 @default.
• W1974947034 hasAuthorship W1974947034A5029122307 @default.
• W1974947034 hasAuthorship W1974947034A5030939291 @default.
• W1974947034 hasAuthorship W1974947034A5031935488 @default.
• W1974947034 hasAuthorship W1974947034A5034645642 @default.
• W1974947034 hasAuthorship W1974947034A5048857512 @default.
• W1974947034 hasAuthorship W1974947034A5053735930 @default.
• W1974947034 hasAuthorship W1974947034A5083214362 @default.
• W1974947034 hasAuthorship W1974947034A5084784449 @default.
• W1974947034 hasConcept C118487528 @default.
• W1974947034 hasConcept C120665830 @default.
• W1974947034 hasConcept C121332964 @default.
• W1974947034 hasConcept C126322002 @default.
• W1974947034 hasConcept C141071460 @default.
• W1974947034 hasConcept C142424586 @default.
• W1974947034 hasConcept C197934379 @default.
• W1974947034 hasConcept C2776194053 @default.
• W1974947034 hasConcept C535046627 @default.
• W1974947034 hasConcept C61511704 @default.
• W1974947034 hasConcept C71924100 @default.
• W1974947034 hasConcept C87355193 @default.
• W1974947034 hasConcept C90924648 @default.
• W1974947034 hasConceptScore W1974947034C118487528 @default.
• W1974947034 hasConceptScore W1974947034C120665830 @default.
• W1974947034 hasConceptScore W1974947034C121332964 @default.
• W1974947034 hasConceptScore W1974947034C126322002 @default.
• W1974947034 hasConceptScore W1974947034C141071460 @default.
• W1974947034 hasConceptScore W1974947034C142424586 @default.
• W1974947034 hasConceptScore W1974947034C197934379 @default.
• W1974947034 hasConceptScore W1974947034C2776194053 @default.
• W1974947034 hasConceptScore W1974947034C535046627 @default.
• W1974947034 hasConceptScore W1974947034C61511704 @default.
• W1974947034 hasConceptScore W1974947034C71924100 @default.
• W1974947034 hasConceptScore W1974947034C87355193 @default.
• W1974947034 hasConceptScore W1974947034C90924648 @default.
• W1974947034 hasIssue "6" @default.
• W1974947034 hasLocation W19749470341 @default.
• W1974947034 hasLocation W19749470342 @default.
• W1974947034 hasOpenAccess W1974947034 @default.
• W1974947034 hasPrimaryLocation W19749470341 @default.
• W1974947034 hasRelatedWork W2003938723 @default.
• W1974947034 hasRelatedWork W2047967234 @default.
• W1974947034 hasRelatedWork W2118496982 @default.
• W1974947034 hasRelatedWork W2275480158 @default.
• W1974947034 hasRelatedWork W2351796763 @default.
• W1974947034 hasRelatedWork W2364998975 @default.
• W1974947034 hasRelatedWork W2439875401 @default.

• next